Stronger is not always better: Could a bodybuilding dietary supplement lead to ALS?

Experimental Neurology

Volumn 228, Issue 1, 2011, Pages 5-8

  Manuel, Marin ^a   Heckman, C J ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

BCAA; Electrophysiology; Environmental factors in ALS; G93A; Hyperexcitability; Persistent sodium current

Indexed keywords

ALANINE; AMPA RECEPTOR; BRANCHED CHAIN AMINO ACID; COPPER ZINC SUPEROXIDE DISMUTASE; GLYCINE; KAINIC ACID RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RAPAMYCIN; RILUZOLE; S6 KINASE; SODIUM ION;

ACTION POTENTIAL; AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; ATHLETE; BODY BUILDING; DIET SUPPLEMENTATION; DISEASE MODEL; DRUG TARGETING; EXCITOTOXICITY; EXERCISE INTENSITY; FOOD COMPOSITION; FOOTBALL; GENE MUTATION; HUMAN; MUSCLE GROWTH; NERVE CELL EXCITABILITY; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; SODIUM CURRENT; SPINAL CORD MOTONEURON; SPORT; SURVIVAL RATE;

AMINO ACIDS, BRANCHED-CHAIN; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DIETARY SUPPLEMENTS; HUMANS; MUSCLE STRENGTH; RESISTANCE TRAINING;

EID: 79851512446     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.12.007     Document Type: Note

References (74)

1. Abel E.L. Football increases the risk for Lou Gehrig's disease, amyotrophic lateral sclerosis. Percept. Mot. Skills 2007, 104:1251-1254.
2. Albo F., Pieri M., Zona C. Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J. Neurosci. Res. 2004, 78:200-207.
3. Armon C. Sports and trauma in amyotrophic lateral sclerosis revisited. J. Neurol. Sci. 2007, 262:45-53.
4. Avruch J., Belham C., Weng Q., Hara K., Yonezawa K. The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog. Mol. Subcell. Biol. 2001, 26:115-154.
5. Balice-Gordon R.J., Smith D.B., Goldman J., Cork L.C., Shirley A., Cope T.C., Pinter M.J. Functional motor unit failure precedes neuromuscular degeneration in canine motor neuron disease. Ann. Neurol. 2000, 47:596-605.
6. Belli S., Vanacore N. Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease?. Eur. J. Epidemiol. 2005, 20:237-242.
7. Beretta S., Carri M.T., Beghi E., Chio A., Ferrarese C. The sinister side of Italian soccer. Lancet Neurol. 2003, 2:656-657.
8. Boillée S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
9. Boillée S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
10. Bradley W.G., Mash D.C. Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph. Lateral Scler. 2009, 10(Suppl 2):7-20.
11. Carlin K.P., Jiang Z., Brownstone R.M. Characterization of calcium currents in functionally mature mouse spinal motoneurons. Eur. J. Neurosci. 2000, 12:1624-1634.
12. Carlin K.P., Jones K.E., Jiang Z., Jordan L.M., Brownstone R.M. Dendritic L-type calcium currents in mouse spinal motoneurons: implications for bistability. Eur. J. Neurosci. 2000, 12:1635-1646.
13. Charcot J., Joffroy A. Deux cas d'atrophie musculaire progressive avec lésions de la substance grise et des faisceaux antéro-latéraux de la moelle épinière. Arch. Physiol. Neurol. Pathol. 1869, 2:744.
14. Cheah B.C., Vucic S., Krishnan A.V., Kiernan M.C. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. 2010, 17:1942-1199.
15. Cheramy A., Barbeito L., Godeheu G., Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci. Lett. 1992, 147:209-212.
16. Cox P.A., Sacks O.W. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology 2002, 58:956-959.
17. Debono M.W., Le Guern J., Canton T., Doble A., Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. 1993, 235:283-289.
18. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996, 47:S233-S241.
19. Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D.J., Ramesh V., Silva A.J. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 2008, 14:843-848.
20. Eisen A., Weber M. The motor cortex and amyotrophic lateral sclerosis. Muscle Nerve 2001, 24:564-573.
21. Ellis C.M., Suckling J., Amaro E., Bullmore E.T., Simmons A., Williams S.C., Leigh P.N. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 2001, 57:1571-1578.
22. Estevez A.G., Stutzmann J.M., Barbeito L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur. J. Pharmacol. 1995, 280:47-53.
23. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5:671-688.
24. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 2004, 185:232-240.
25. Frey D., Schneider C., Xu L., Borg J., Spooren W., Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J. Neurosci. 2000, 20:2534-2542.
26. Gong Y.H., Parsadanian A.S., Andreeva A., Snider W.D., Elliott J.L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 2000, 20:660-665.
27. Greig A., Donevan S.D., Mujtaba T.J., Parks T.N., Rao M.S. Characterization of the AMPA-activated receptors present on motoneurons. J. Neurochem. 2000, 74:179-191.
28. Grosskreutz J., Van den Bosch L., Keller B.U. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium 2010, 47:165-174.
29. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
30. Hegedus J., Putman C.T., Gordon T. Time course of preferential motor unit loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2007, 28:154-164.
31. Hegedus J., Putman C.T., Tyreman N., Gordon T. Preferential motor unit loss in the SOD1 G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Physiol. 2008, 586:3337-3351.
32. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
33. Ince P.G. Neuropathology. Amyotrophic Lateral Sclerosis 2000, Martin Dunitz, London. R. Brown, V. Meininger, M. Swash (Eds.).
34. Jiang M., Schuster J.E., Fu R., Siddique T., Heckman C.J. Progressive changes in synaptic inputs to motoneurons in adult sacral spinal cord of a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2009, 29:15031-15038.
35. Karlsborg M., Rosenbaum S., Wiegell M., Simonsen H., Larsson H., Werdelin L., Gredal O. Corticospinal tract degeneration and possible pathogenesis in ALS evaluated by MR diffusion tensor imaging. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2004, 5:136-140.
36. Kiernan M.C. Hyperexcitability, persistent Na+conductances and neurodegeneration in amyotrophic lateral sclerosis. Exp. Neurol. 2009, 218:1-4.
37. Kuo J.J., Schonewille M., Siddique T., Schults A.N.A., Fu R., Bär P.R., Anelli R., Heckman C.J., Kroese A.B.A. Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice. J. Neurophysiol. 2004, 91:571-575.
38. Le Liboux A., Lefebvre P., Le Roux Y., Truffinet P., Aubeneau M., Kirkesseli S., Montay G. Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J. Clin. Pharmacol. 1997, 37:820-827.
39. Li Y., Gorassini M.A., Bennett D.J. Role of persistent sodium and calcium currents in motoneuron firing and spasticity in chronic spinal rats. J. Neurophysiol. 2004, 91:767-783.
40. Lino M.M., Schneider C., Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 2002, 22:4825-4832.
41. Lips J., de Haan P., Bodewits P., Vanicky I., Dzoljic M., Jacobs M.J., Kalkman C.J. Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit. Anesthesiology 2000, 93:1303-1311.
42. Malgouris C., Daniel M., Doble A. Neuroprotective effects of riluzole on N-methyl-d-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci. Lett. 1994, 177:95-99.
43. Manuel M., Iglesias C., Donnet M., Leroy F., Heckman C.J., Zytnicki D. Fast kinetics, high-frequency oscillations, and subprimary firing range in adult mouse spinal motoneurons. J. Neurosci. 2009, 29:11246-11256.
44. Martin D., Thompson M.A., Nadler J.V. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 1993, 250:473-476.
45. Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2007, CD001447.
46. Mills K.R., Nithi K.A. Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Muscle Nerve 1997, 20:1137-1141.
47. Nair G., Carew J.D., Usher S., Lu D., Hu X.P., Benatar M. Diffusion tensor imaging reveals regional differences in the cervical spinal cord in amyotrophic lateral sclerosis. Neuroimage 2010, 53:576-583.
48. Ohtani M., Sugita M., Maruyama K. Amino acid mixture improves training efficiency in athletes. J. Nutr. 2006, 136:538S-543S.
49. Palecek J., Lips M.B., Keller B.U. Calcium dynamics and buffering in motoneurones of the mouse spinal cord. J. Physiol. 1999, 520(Pt 2):485-502.
50. Pambo-Pambo A., Durand J., Gueritaud J. Early excitability changes in lumbar motoneurons of transgenic SOD1G85R and SOD1G93A-Low mice. J. Neurophysiol. 2009, 102(6):3627-3642.
51. Park K.H.J., Vincent I. Presymptomatic biochemical changes in hindlimb muscle of G93A human Cu/Zn superoxide dismutase 1 transgenic mouse model of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2008, 1782:462-468.
52. Parkhouse W.S., Cunningham L., McFee I., Miller J.M.L., Whitney D., Pelech S.L., Krieger C. Neuromuscular dysfunction in the mutant superoxide dismutase mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2008, 9:24-34.
53. Pieri M., Carunchio I., Curcio L., Mercuri N.B., Zona C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp. Neurol. 2009, 215:368-379.
54. Pramatarova A., Laganiere J., Roussel J., Brisebois K., Rouleau G.A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 2001, 21:3369-3374.
55. Pun S., Santos A.F., Saxena S., Xu L., Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 2006, 9:408-419.
56. Purdey M. Elevated levels of ferrimagnetic metals in foodchains supporting the Guam cluster of neurodegeneration: do metal nucleated crystal contaminants [corrected] evoke magnetic fields that initiate the progressive pathogenesis of neurodegeneration?. Med. Hypotheses 2004, 63:793-809.
57. Quinlan K.A., ElBasiouny S.M., Heckman C.J. Increased excitability in juvenile SOD1 motoneurons Program No. 304.11. 2009 Neuroscience Meeting Planner 2009, Society for Neuroscience, Chicago, IL, 2009. Online.
58. Reed D., Labarthe D., Chen K.M., Stallones R. A cohort study of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and Rota. Am. J. Epidemiol. 1987, 125:92-100.
59. Sandsmark D.K., Pelletier C., Weber J.D., Gutmann D.H. Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol. Histopathol. 2007, 22:895-903.
60. Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 2005, 17:596-603.
61. Sasaki S., Iwata M. Ultrastructural change of synapses of Betz cells in patients with amyotrophic lateral sclerosis. Neurosci. Lett. 1999, 268:29-32.
62. Siniscalchi A., Bonci A., Mercuri N.B., Bernardi G. Effects of riluzole on rat cortical neurones: an in vitro electrophysiological study. Br. J. Pharmacol. 1997, 120:225-230.
63. Spilman P., Podlutskaya N., Hart M.J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e9979.
64. Steele J.C., McGeer P.L. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 2008, 70:1984-1990.
65. Stevenson A., Yates D.M., Manser C., De Vos K.J., Vagnoni A., Leigh P.N., McLoughlin D.M., Miller C.C. Riluzole protects against glutamate-induced slowing of neurofilament axonal transport. Neurosci. Lett. 2009, 454:161-164.
66. Urbani A., Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur. J. Neurosci. 2000, 12:3567-3574.
67. Van Damme P., Van den Bosch L., Van Houtte E., Callewaert G., Robberecht W. GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity. J. Neurophysiol. 2002, 88:1279-1287.
68. Van den Bosch L., Van Damme P., Vleminckx V., Van Houtte E., Lemmens G., Missiaen L., Callewaert G., Robberecht W. An alpha-mercaptoacrylic acid derivative (PD150606) inhibits selective motor neuron death via inhibition of kainate-induced Ca2+ influx and not via calpain inhibition. Neuropharmacology 2002, 42:706-713.
69. Van den Bosch L., Vandenberghe W., Klaassen H., Van Houtte E., Robberecht W. Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J. Neurol. Sci. 2000, 180:29-34.
70. van Zundert B., Peuscher M.H., Hynynen M., Chen A., Neve R.L., Brown R.H., Constantine-Paton M., Bellingham M.C. Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J. Neurosci. 2008, 28:10864-10874.
71. Vanacore N., Binazzi A., Bottazzi M., Belli S. Amyotrophic lateral sclerosis in an Italian professional soccer player. Parkinsonism Relat. Disord. 2006, 12:327-329.
72. Vanselow B.K., Keller B.U. Calcium dynamics and buffering in oculomotor neurones from mouse that are particularly resistant during amyotrophic lateral sclerosis (ALS)-related motoneurone disease. J. Physiol. 2000, 525(Pt 2):433-445.
73. Vucic S., Nicholson G.A., Kiernan M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008, 131:1540-1550.
74. Zanette G., Tamburin S., Manganotti P., Refatti N., Forgione A., Rizzuto N. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin. Neurophysiol. 2002, 113:1688-1697.